Oncology

Download Brochure


Oncology

Cancer known medically as a malignant neoplasm, is a broad group of various diseases, all involving unregulated cell growth. In cancer, cells divide and grow uncontrollably, forming malignant tumours, and invade nearby parts of the body. The cancer may also spread to more distant parts of the body. There are over 200 different known cancers that afflict humans. Cancer is the subject of widespread fear and taboos. There is a deep belief that cancer is necessarily a difficult and usually deadly disease.

Shilpa offers a comprehensive, high-quality portfolio and a dynamic pipeline of oncology drugs, which are beyond standard generics. We have a broad portfolio of 25 + products and a robust pipeline that addresses the needs of cancer treatment. By further growing our portfolio and strengthening our global presence, Shilpa will ensure that patients worldwide have greater access to a comprehensive range of these vital quality medicines at an affordable cost. We are proud to assert that the field of Oncology is one of our core competencies and we offer a comprehensive range of APIs and Finished Dosage Forms in this segment.

For more information on Shilpa‘s pipeline/products to treat cancer, Please find below Oncology product list.

Oncology API’s

Oncology API Tech Pack DMF Status
Open Part US EU TPD PMDA TGA EDQM KFDA GCC Medsafe DMF Number
Anastrozole                     USDMF# 29654
Axitinib                     USDMF# 30104
Azacitidine                   USDMF#27487
Abiraterone Acetate                     Tech. Pack available
Bendamustine HCL Monohydrate                 USDMF# 25222
Bicalutamide               USDMF# 24690
Bortezomib               USDMF# 24944
Busulphan               R0-CEP 2011-339-Rev 01, USDMF# 25491
Cabazitaxel Amorphous                     Tech. Pack available
Capecitabine         R0-CEP 2014-332-Rev 00, USDMF# 24689
Carboplatin                    
Cladribine                      
Clofarabine                     USDMF# 29806
Cyclophosphamide Monohydrate                      
Cytarabine                      
Dasatinib                     Tech. Pack available
Decitabine                   USDMF# 27488
Docetaxel                    
Erlotinib HCL                   USDMF# 29124
Enzalutamide                     USDMF# 30260
Gemcitabine HCl     R1-CEP 2006-222-Rev 00, USDMF # 24136
Gefitinib                      
Hydroxy Urea                      
Imatinib Mesylate                   R0-CEP-2016-121-Rev 01, USDMF# 27927
Irinotecan HCl Trihydrate         USDMF# 23562
Lenalidomide                     Tech. Pack available
Letrozole                   R0-CEP 2013-321-Rev 00, USDMF # 27489
Melphalan HCL                     USDMF# 28930
Oxaliplatin       R1-CEP 2006-201-Rev 00, USDMF # 23563
Paclitaxel                   Tech. Pack available
Pazopanib                      
Pemetrexed Disodium Hemipentahydrate                 USDMF# 25102
Pemetrexed DiPotassium Nonahydrate                     USDMF# 29652
Regorafinib                      
Sorafenib                     Tech. Pack available
Sunitinib                     Tech. Pack available
Temozolomide         R0-CEP 2016-277-Rev 00, USDMF# 23479,
Thalidomide                   Tech. Pack available
TopotecanHCl                      
Vismodegib                      
Zoledronic acid                   USDMF# 25905
5- Fluoro Uracil                      

Under Development-Oncology API’s

PRODUCTS UNDER DEVELOPMENT (Oncology)
Afatinib Dimaleate Lapatinib Distosylate Ponatinib
Alectinib Lenvatinib Mesylate Regadenoson Monohydrate
Bexarotene Mecitentan Ribociclib Succinate
Citicholine Methotraxate Rucaparib Camasylate
Crizotinib Neratinib Malate Safinamide
Dabrafenib Nilotinib Selexipag
Edoxaban Nintedanib Silodosin
Elagolix Olaparib Succinylcholine
Eltrombopag Olamine Osimertinib Trametinib
Exemestane Palbociclib Varenicline Tartrate
Glycopyyrolate Panobinostate Lactate Vemurafenib
Ibrutinib Pazopanib HCl Venetoclax
Idelalisib Plerixafor Vismodegib
Ixazomib Pomalidomide Bosutinib
Vemurafenib Crizotinib Lapatinib Ditosylate
Carfilzomib Afatinib Nilotinib
Nintedanib Ibrutinib Mecitentan
Pomalidomide Vismodegib

* PRODUCTS UNDER VALID PATENTS ARE NOT OFFERED FOR COMMERCIAL OPERATIONS:
ONLY R&D QUANTITIES ARE OFFERED.

For Enquiries, please contact

Shilpa Medicare Limited

#12-6-214/A1, Hyderabad Road,
Raichur – 584 135, Karnataka.
Tel: +91-8532-235006, Fax: +91-8532-235876
eMail: info@vbshilpa.com, vishnu@vbshilpa.com